Ticker brief

BNTX BIONTECH SE-ADR

Consumer, Non-cyclical · Biotechnology

last close
$102.08
1 day
-8.4%
14 days
+9.7%
mkt cap
$24.7B
signals 14d
52
authors 14d
35
crowd 14d
+0.2σ
Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d48% rich · 85 pctile own 1yIV/HV 0.77× (as of 2026-08-27)
Skew — 25Δ RR 30d+0.022 82 pctile own 1ycalls bid vs puts (call skew rich)
Net dealer OI (NDOI)+0.02 normal5-session Δ -0.01 (as of 2026-07-16)
OI alarmquietlast alarm 2026-03-11 (z=3.4)
Sentiment — last 14 days
daily mean sentiment, 2026-08-19 → 2026-08-28 · now -0.32 (−1 bearish … +1 bullish)
Who spoke35
authorgradetrader scoresignalsmean sent
@Markadiusz45C+1.185+0.42
@PharmdcaC+0.825-0.19
@bioinvestor24A-0.454-0.36
@schaeffersC+3.183+0.60
@markflowchatterB+2.002-0.08
@Brad_E_SchulzC·2+0.70
@toushi_tommyC-1.162+0.50
@MarketNews_FeedC·2-0.50
@BankTheTradeC+1.631+0.45
@nextbigtradeB+1.101+0.45
@KakashiCapital_B-0.151+0.35
@TrendSpiderC-1.011+0.30
@KampnerSamA+0.201+0.20
@semodoughC-3.011+0.20
@BottomPhishingB-1.201+0.30
@IPODaveB+1.631+0.65
@kunal00C-0.851+0.55
@equityddC-2.031+0.20
@IngJuanPa7B-1.611+0.15
@JensKlattFXB+0.501-0.10
@cfaryanoconnellC-1.481-0.10
@ClassicRoyC-1.521-0.25
@TheOwlsCapitalC+0.581+0.85
@RichardMoglenB-0.931+0.35
@kiantradesC+0.691+0.70
Recent signals30of 52 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-08-28@fwpharma-0.45BioNTech ends a colorectal study of its mRNA vaccine.
2026-08-28@bioinvestor24-0.55Discloses no MRNA position but a positive trial view, and states a current HK1952 position viewed as undervalued.
2026-08-28@bioinvestor24-0.70Mocks BNTX's colorectal-cancer strategy and favors MRNA's platform and tumor-selection approach.
2026-08-28@BiotechCH-0.55BNTX announced it is halting its colorectal-cancer vaccine trial.
2026-08-28@ttvresearch-0.50BioNTech ended a Phase 2 colorectal-cancer trial, prompting sharp declines in related biotech shares.
2026-08-28@MarketNews_Feed-0.50BioNTech ended a Phase 2 colorectal-cancer clinical trial.
2026-08-28@MarketNews_Feed-0.50BioNTech stopped a Phase 2 colorectal-cancer trial after a DSMB recommended ending treatment and the study.
2026-08-28@markflowchatter+0.40Praises a Leerink analyst's prior BNTX call but does not specify its terms.
2026-08-28@Tradinguru55+0.50Pfizer and BioNTech received approval for an updated COVID-19 vaccine.
2026-08-27@HammerstoneMar3+0.50Pfizer and BioNTech received FDA approval for an XFG-adapted COVID-19 vaccine.-8.4%
2026-08-27@faststocknewss+0.50FDA approves updated COVID vaccine formulas from Pfizer-BioNTech and Moderna.-8.4%
2026-08-27@EchoAnalysis+0.70States BNTX is close to a potentially violent breakout.-8.4%
2026-08-23@fundmyfund+0.65Bullish BNTX sympathy setup seeks a breakout-gap hold and continued upside.-12.4%
2026-08-22@toushi_tommy+0.60Summarizes weekly index performance and top and bottom securities.-12.4%
2026-08-22@dangerousteee+0.00Reports weekly winners and losers with exact percentage returns by sector.-12.4%
2026-08-21@stageanalysis+0.25Screen identifies Stage 2 and continuation-breakout candidates using explicit technical filters.-12.4%
2026-08-21@kiantrades+0.70Reports a completed BNTX move from 2.4 to 15 alongside a chart.-12.4%
2026-08-21@RichardMoglen+0.35BNTX moved back above a high-volume technical area.-12.4%
2026-08-20@TheOwlsCapital+0.85Weekly options recap lists entries, gains and one still-running position.-7.9%
2026-08-20@ClassicRoy-0.25Lists equities experiencing increasing unusual put volume.-7.9%
2026-08-20@cfaryanoconnell-0.10Lists stocks with increasing unusual put-option volume.-7.9%
2026-08-20@Pharmdca-0.40Reports covering a short near $107 after entering near $114 the prior day.-7.9%
2026-08-20@JensKlattFX-0.10Maps public cancer-vaccine peers, sympathy moves, clinical prospects, and M&A potential-7.9%
2026-08-20@IngJuanPa7+0.15MRK-MRNA personalized cancer vaccine met endpoints in a 1,000-plus-patient late-stage trial.-7.9%
2026-08-20@Markadiusz45+0.50Portfolio update discloses stopped positions, new biotech longs and partial BNTX derisking.-7.9%
2026-08-19@equitydd+0.20Lists the day's leading gainers; ticker extraction is capped at the first six.-9.8%
2026-08-19@bioinvestor24+0.05Quotes Everest's CEO claiming end-to-end mRNA and in-vivo CAR-T capabilities comparable with large peers.-9.8%
2026-08-19@bioinvestor24-0.25Says private Everest's platform is better than BioNTech's.-9.8%
2026-08-19@kunal00+0.55Frames QE, biotech, crypto and software rotation while presenting a next-day watchlist.-9.8%
2026-08-19@schaeffers+0.60Reports successful Phase 3 melanoma results and quantified peer and sector gains.-9.8%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.